NCT02135042 2026-03-18
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Phase 2/3 Active not recruiting
NRG Oncology
National Cancer Institute (NCI)
Regeneron Pharmaceuticals
Alliance for Clinical Trials in Oncology
Australasian Gastro-Intestinal Trials Group
Fudan University
RenJi Hospital